Novavax | NVAX - Interest Expense On Debt

Novavax reported $4.6M in Interest Expense on Debt for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Interest Expense On Debt Change
Adma Biologics ADMA:US USD 5.58M 1.01M
Biocryst Pharmaceuticals BCRX:US USD 26.46M 1.68M
Dynavax Technologies DVAX:US USD 1.68M 1000
Geron GERN:US USD 1.82M 236K
Mannkind MNKD:US USD 5.29M 9K
Moderna Inc MRNA:US USD 10M 2M
Novartis NVS:US USD 219M 4M
Novavax NVAX:US USD 4.6M 432K
Pfizer PFE:US USD 313M 2M
Sarepta Therapeutics SRPT:US USD 6.69M 8.05M
Tg Therapeutics TGTX:US USD 2.86M 1.21M